Previous studies have shown that TGFBR3 produces anticancer activities via regulating invasion, proliferation, cell migration and angiogenesis and that expression of TGFBR3 is decreased in a variety of malignancies such as breast, kidney, lung, ovary, pancreas and prostate cancers [20]. The gene discussed is TGFBR3; the disease is prostate carcinoma.